When will vamorolone be available?

Catalystis the U.S. licensee ofvamorolone(vamorolone) planned for 2024Commercial preparations will be made inQ1 in February2. 2023YearOctoberMonth26The U.S. Food and Drug Administration(FDA)approvedSanthera Pharmaceuticals' varmorolone oral suspension at 40 mg/ml marks an important milestone in the treatment of Duchenne muscular dystrophy (DMD) in adults and children 2 years of age and older. Vamoroloneis the first drug candidate to bind to the corticosteroid receptor but alters the receptor's downstream activity1,2 . If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.